Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03800173 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
A Phase 1 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03800173 is a Phase 1 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT03800173, a Phase 1 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
Interventions
- DRUG placebo
- DRUG galidesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2019-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03800173
The ClinicalTrials.gov registry entry for NCT03800173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03800173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03800173 about?
NCT03800173 is a clinical study titled "A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430". This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
What is the current status of trial NCT03800173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-12-10. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03800173?
The interventions under investigation include: placebo (DRUG), galidesivir (DRUG).
Who is sponsoring clinical trial NCT03800173?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.